News | November 07, 2022
Balaxi Pharmaceuticals delivers strong growth in Q2 FY23
Revenue is up 23% whereas Profit After Tax expands 29% for the company
Revenue is up 23% whereas Profit After Tax expands 29% for the company
API platform to comprise of RA Chem Pharma, ZCL Chemicals and Avra Laboratories
The participants discussed the latest developments under ABDM that shall enable true interoperability in the health sector and how effective adoption of ABDM can pave the way towards Universal Health Coverage
NFIL’s ambition is to reach revenues of US$100mn from CDMO by FY25.
The company currently supplies one product to the US market that contributes low- single digit revenue to Jubilant Pharmova revenue
Once the unit is made fully functional, it will help the company in increasing its API and intermediate production capacity
Indigenously-developed molecular diagnostics have helped expand the reach of diagnosis to every part of the country today
India will become a digital health leader, as we have the world’s best technical manpower required and our data is the cheapest in the world, approaching 100 percent coverage
Frazier led the company for 10 years as President and Chief Executive Officer, from 2011 through 2021.
Oncodesign Services (ODS ), with 600 clients in 33 countries and 227 employees worldwide, provides services from target identification to hit-to-lead and lead optimization through to IND filing.
Subscribe To Our Newsletter & Stay Updated
